It is very uncertain whether benzodiazepines changes tardive dyskinesia: no clinically important improvement compared with phenobarbital (as active placebo) (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether benzodiazepines changes adverse events: any compared with phenobarbital (as active placebo) (very low certainty).
Rutosides may leads to lower improvement in PTS (6 months) compared with an alternative venoactive remedy (hidrosmina) (low certainty).
Rutosides showed no clear difference in deterioration in PTS (6 months) compared with an alternative venoactive remedy (hidrosmina) (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
One infusion of natalizumab (300 mg or 3 mg/kg) probably leads to lower failure to induce remission at 2 weeks compared with placebo (moderate certainty).
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in failure to induce clinical response at 6 weeks compared with placebo (low certainty).
Two infusions of natalizumab (300 mg or 3 mg/kg) may leads to lower faliure to induce clinical response at 8 weeks compared with placebo (low certainty).
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in adverse events up to week 12 compared with placebo (moderate certainty).
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).
Two infusions of natalizumab (6 mg/kg) showed no clear difference in failure to induce remission at 6 weeks compared with placebo (moderate certainty).
Two infusions of natalizumab (6 mg/kg) showed no clear difference in failure to induce clinical response at 6 weeks compared with placebo (moderate certainty).
Two infusions of natalizumab (6 mg/kg) showed no clear difference in adverse events up to week 12 compared with placebo (moderate certainty).
One infusion of natalizumab (300 mg or 3 mg/kg) leads to lower failure to induce remission at 4 weeks compared with placebo (high certainty).
Two infusions of natalizumab (6 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).
Two infusions of natalizumab (6 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).
Three infusions of natalizumab (300 mg) showed no clear difference in failure to induce remission at 10 weeks compared with placebo (high certainty).